CymitQuimica logo

CAS 199463-33-7

:

Revaprazan

Description:
Revaprazan is a novel compound classified as a potassium-competitive acid blocker (P-CAB), primarily used for the treatment of acid-related gastrointestinal disorders. It functions by selectively inhibiting the gastric H+/K+-ATPase enzyme, which plays a crucial role in gastric acid secretion. This mechanism allows Revaprazan to effectively reduce gastric acidity, providing relief from conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. The substance is characterized by its high potency and rapid onset of action compared to traditional proton pump inhibitors (PPIs). Revaprazan is typically administered orally and exhibits a favorable pharmacokinetic profile, including good bioavailability and a relatively long half-life, which supports once-daily dosing. Additionally, it has been noted for its lower potential for drug-drug interactions, making it a suitable option for patients on multiple medications. Overall, Revaprazan represents a promising advancement in the management of acid-related disorders, offering an alternative therapeutic approach with distinct advantages over existing treatments.
Formula:C22H23FN4
InChI:InChI=1S/C22H23FN4/c1-14-15(2)24-22(25-19-10-8-18(23)9-11-19)26-21(14)27-13-12-17-6-4-5-7-20(17)16(27)3/h4-11,16H,12-13H2,1-3H3,(H,24,25,26)
InChI key:InChIKey=LECZXZOBEZITCL-UHFFFAOYSA-N
SMILES:CC1N(CCC=2C1=CC=CC2)C3=NC(NC4=CC=C(F)C=C4)=NC(C)=C3C
Synonyms:
  • Revaprazan
  • 4-(3,4-Dihydro-1-methyl-2(1H)-isoquinolinyl)-N-(4-fluorophenyl)-5,6-dimethyl-2-pyrimidinamine
  • YH 1885 free base
  • 2-Pyrimidinamine, 4-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)-N-(4-fluorophenyl)-5,6-dimethyl-
  • SB 641257
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 2 products.